Holding Back the Years
January 21, 2019
Seeking inspiration from plants in the fight against Alzheimer’s disease
0 min read
December 2018
Welcome to the December issue. Upfront explores Brexit and the UK’s current Withdrawal Agreement woes, transdermal patches for drug delivery, and the exploitation of CRISPR technology to modify embryonic genomes. Giovanni Appendino explains why we should tap into the medical potential of cannabis in “In My View,” while our cover feature highlights the most innovative technologies of the past year with our Innovation Awards. And Gavin Yamey discusses how a new financial modelling tool can help bridge the funding gap for neglected diseases in “Business.” In our latest Sitting Down With… Stanley Crooke, CEO at Ionis Pharmaceuticals argues that weathering the storm when creating new platforms can lead to positive outcomes.
Medicines Anywhere, Anytime
January 21, 2019
Why use a huge manufacturing facility when biological medicines can be made in a suitcase?
0 min read
Staying the Course
January 18, 2019
Sitting Down With… Stanley Crooke, Chairman of the Board & Chief Executive Officer at Ionis Pharmaceuticals.
0 min read
Here's to Good Science for 2019
January 15, 2019
Successes in the cell and gene therapy field show us that great advances can be made – without taking unnecessary risks.
0 min read
Skin Deep Problems
January 15, 2019
A flexible, synthetic patch helps eliminate the toxicity and invasiveness associated with long-term drug delivery
0 min read
Spiraling Towards an Answer
January 15, 2019
Researchers capture the interactions of antibodies with the parasite responsible for malaria for the first time
0 min read
Always the Bridesmaid...
January 15, 2019
Although research and development for neglected diseases now commands a significant amount of attention, a new financial modeling tool shows that there is still a major funding gap.
0 min read
Withdrawal Symptoms
January 8, 2019
As UK politicians debate the merits of the Prime Minister’s Withdrawal Agreement, we debate its potential impact for pharma...
0 min read
Crossing the Rubicon
January 8, 2019
What does the controversial genome editing work of Jiankui He mean for biomedical research?
0 min read
Business-in-Brief
January 8, 2019
Oscars of science, drug shortage reporting requirements, and a new gene therapy... What’s new for pharma in business?
0 min read
